The growth hormone-insulin-like growth factor axis in kidney re-revisited.
The use of renal allotransplantation to treat ESRD in the US is limited by lack of organ availability. A possible solution is the transplantation of developing kidneys (metanephric allograft or xenografts). We have conducted studies that demonstrate the feasibility of such a strategy and have shown that IGF I may be useful to accelerate the growth and development of these transplanted organs. The rationale for the use of IGF I in this setting grew from a basic understanding of the role that the growth factor plays in kidney development. ARF in humans is the most costly kidney-related disease requiring hospitalization. Its incidence is increasing. Despite many advances in dialytic therapy, the mortality rate for patients with ARF has not changed in the last several decades. Strategies for treatment of ARF are directed toward supportive care to permit renal regeneration to occur. There exists a need for new therapeutic approaches that can speed recovery and reduce mortality. Although IGF I may not prove to be the 'magic bullet' for ARF, its proposal and testing as a potential therapeutic agent has provided a paradigm for the development of treatment modalities to accelerate renal regeneration based upon a basic understanding of the injury/repair process. The basis for development of a 'growth factor' therapy for ARF will probably evolve, at least in part, out of the testing and use of IGF I in rat models and in humans. The use of GH to treat ESRD was proposed shortly after its isolation and the demonstration of its action in increasing the rate of glomerular filtration. Later, it was discovered that the actions of GH on kidney are mediated by IGF I, and the means by which IGF I enhances glomerular filtration was elucidated. We have shown that humans with ESRD are not resistant to the actions of IGF I in enhancing the GFR, establishing the potential for use of IGF I as a pharmacological agent for ESRD. There is no effective drug therapy to enhance renal function in ESRD. Although much work remains to be done, and clearly caution is advised, our observations establish the potential for the use of IGF I as a therapeutic agent in this setting and justify continued study of IGF I as a medical therapy to delay the need for dialysis.
Hammerman
M R
MR
George M. O'Brien Kidney and Urological Diseases Center, Department of Internal Medicine and Cell Biology and Physiology, Washington University School of Medicine, St Louis, MO 63110, USA.
D058186:Acute Kidney Injury / Q000628:therapy; D000818:Animals; D005314:Embryonic and Fetal Development / Q000502:physiology; D016332:Fetal Tissue Transplantation; D013006:Growth Hormone / Q000502:physiology* / Q000627:therapeutic use; D019382:Human Growth Hormone / Q000502:physiology / Q000627:therapeutic use; D006801:Humans; D007668:Kidney / Q000196:embryology / Q000502:physiology*; D007676:Kidney Failure, Chronic / Q000628:therapy; D013002:Somatomedins / Q000502:physiology* / Q000627:therapeutic use
D013002:Somatomedins; D019382:Human Growth Hormone; D013006:Growth Hormone